Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
PARP inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
L01XX60
|
| gptkbp:brand |
gptkb:Talzenna
|
| gptkbp:CASNumber |
1207456-01-6
|
| gptkbp:chemicalFormula |
C19H14F2N6O
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
90 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
talazoparib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PARP inhibition
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
380.36 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue neutropenia thrombocytopenia |
| gptkbp:target |
gptkb:PARP1
gptkb:PARP2 |
| gptkbp:usedFor |
gptkb:cancer
BRCA-mutated breast cancer |
| gptkbp:bfsParent |
gptkb:Medivation
|
| gptkbp:bfsLayer |
5
|